Physician profile
Bruce Mann
NPI 1285607911
$7,407.77
in general payments reported to CMS, 2019-2025
41 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what 76% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $935 · 2021: $498 · 2022: $1,376 · 2023: $1,231 · 2024: $1,061 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,023.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,383.66 | 2019-2025 | Relistor |
| Medtronic, INC. | $665.50 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $599.53 | 2019-2024 | Ztlido |
| Relievant Medsystems, INC. | $486.66 | 2022 | |
| Forte Bio-Pharma LLC | $450.09 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Spr Therapeutics, INC | $368.89 | 2023-2025 | Sprint Pns System |
| Abbott Laboratories | $335.36 | 2019-2025 | Proclaim, Eterna |
| Collegium Pharmaceutical, INC. | $294.13 | 2019-2025 | Belbuca, Xtampza |
| Globus Medical, INC. | $244.03 | 2025 | Vyrsa V1, Senza |
| Valinor Pharma, LLC | $223.59 | 2023-2025 | Movantik |
| Biotronik Nro, INC. | $217.74 | 2024-2025 | Prospera |
| Ipsen Biopharmaceuticals, INC | $184.99 | 2022 | |
| Avanos Medical | $174.89 | 2019-2021 | |
| Vertos Medical, INC. | $166.86 | 2021-2023 | Mild Device Kit |
| Painteq LLC | $162.90 | 2024 | Painteq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.